Perspectives on regulatory T cell therapies

Transfusion Medicine and Hemotherapy

Volumn 36, Issue 5, 2009, Pages 302-308

  Probst Kepper, Michael ^a   Kröger, Andrea ^a   Garritsen, Henk S P ^b   Buer, Jan ^c  

^a KLINIKUM BRAUNSCHWEIG   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

CD4+ CD25+ regulatory T cells; FOXP3; GARP; Positive feedback loop

Indexed keywords

PROTEIN; PROTEIN GARP; PROTEIN LRRC32; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; AUTOIMMUNE DISEASE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE TRANSFER; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 70449397393     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235929     Document Type: Review

References (53)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
2. Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4:337-342.
3. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4: 330-336.
4. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
5. Ochs HD, Ziegler SF, Torgerson TR: FOXP3 acts as a rheostat of the immune response. Immunol Rev 2005;203:156-164.
6. Ziegler SF: FOXP3: of mice and men. Annu Rev Immunol 2006;24:209-226
7. Gavin MA, Torgerson TR, Houston E, deRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD, Rudensky AY: Single- cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006;103:6659-6664.
8. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK: Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007;19:345-354.
9. Wang F, Ioan-Facsinay A, Van Der Voort EIH, Huizinga TW, Toes RE: Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007;37:129-138.
10. Tran DQ, Ramsey H, Shevach EM: Induction of FOXP3 expression in naive human CD4+FOXP3- T cells by T cell receptor stimulation is TGFβ-dependent but does not confer a regulatory phenotype. Blood 2007;110:2983-2990.
11. Ocklenburg F, Moharregh-Khiabani D, Geffers R, Janke V, Pfoertner S, Garritsen H, Groebe L, Klempnauer J, Dittmar KE, Weiss S, et al.: UBD, a downstream element of FOXP3, allows the identification of LGALS3, a new marker of human regulatory T cells. Lab Invest 2006;86:724-737.
12. Probst-Kepper M: Conjunctival FOXP3 in trachoma: T cells not specified. PLoS Med 2006;3:e506.
13. Probst-Kepper M, Geffers R, Kröger A, Viegas N, Erck C, Hecht HJ, Lünsdorf H, Roubin R, Moharregh- Khiabani D, Wagner K, et al.: GARP: A key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med 2009;DOI: 10.1111/j.1582- 4934.2009.00782.x.
14. Stokis J, Fink W, Francois V, Connerotte T, de Smet C, Knoops L, van der Bruggen P, Coulie PG, Lucas S: Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol 2009;39:869-882.
15. Francois V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, et al.: The CD4+ T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 2009;69:4335-4354.
16. Roncarolo MG, Gregori S: Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008;38:925-927.
17. Hori S: Rethinking the molecular definition of regulatory T cells. Eur J Immunol 2008;38:901-937.
18. Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D: Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PLoS ONE 2008;3: e27705.
19. Tran DQ, Shevach EM: Therapeutic potential of FOXP3 regulatory T cells and their interactions with dendritic cells. Hum Immunol 2009;70:294-299.
20. Schmidl C, Klug M, Boeld TJ, Andreesen R, Hoffmann P, Edinger M, Rehli M: Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res 2009;19:1165-1174.
21. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, et al.: Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007;5:e38.
22. Demotte N, Stroobant V, Van Der Smissen P, Colau D, Luescher EF, Hivroz C, Nicaise C, Squifflet J, Mourad M, Godelaine D, et al.: Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008;28:414-424.
23. Reinwald S, Wiethe C, Westendorf AM, Breloer M, Probst-Kepper M, Fleischer B, Steinkasserer A, Buer J, Hansen W: CD83 expression in CD4+ T cells modulates inflammation and autoimmunity. J Immunol 2008;180:5890-5897.
24. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM: CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 2008;110:2537-2544.
25. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA: In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004;199:1455-1465.
26. Mukherjee R, Chaturvedi P, Qin HY, Singh B: CD4+CD25+regulatory T cells generated in response to insulin B:9-23 peptide prevent adoptive transfer of diabetes by diabetogenic T cells. J Autoimmun 2003;21:221-237.
27. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004;199:1467-1477.
28. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL: CD4+CD25+ immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002;196:401-406.
29. Taylor PA, Lees CJ, Blazar BR: The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99:3493-3499.
30. Nishimura E, Sakihama T, Setoguchi R, Tanaka K, Sakaguchi S: Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells. Int Immunol 2004;16:1189-1201.
31. Riley JL, June CH, Blazar BR: Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009;30:656-665.
32. Reed W, Noga SJ, Gee AP, Rooney CM, Wagner JE, McCullough J, McKenna DH, Whiteside TL, Donnenberg AD, Baker AK, et al.: Production Assistance for Cellular Therapies (PCAT): five-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies. Transfusion 2009;49:786-796.
33. Rezvani AR, Storb RF: Separation of graft-vs.- tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplatation. J Autoimmun 2008;30:172-179.
34. Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, Bacchetta R, Levings MK: CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev 2008;223:391-421.
35. Seddiki N, Santner-Nanan B, Tangye SG, Alexander Sl, Solomon M, Lee S, Nanan R, Fazekas de Saint Groth B: Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006;107:2830-2838.
36. Pfoertner S, Jeron A, Probst-Kepper M, Guzman CA, Hansen W, Westendorf AM, Toepfer T, Schrader AJ, Franzke A, Buer J, et al.: Signatures of human regulatory T Cells: An encounter with old friends and new players. Genome Biol 2006;7:R54- 1-R54-18.
37. Trzonkowski P, Szaryñska M, Mysliwska J, Mysliwski A: Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytometry 2009;75:175-188.
38. Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG, Shevach EM: Selective expression of latencyassociated peptide (LAP) and IL-1 receptor type I/ II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 2009;113:5125-5133.
39. Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJPM, Joosten I: Clinical grade Treg: GMP isolation, improvement of purity by CD127pos depletion, Treg expansion, and Treg cryopreservation. PLoS ONE 2009;3:e3161.
40. Thurner B, Röder C, Dieckmann D, Heuer M, Kruse M, Keikavoussi P, Kämpgen E, Bender A, Schuler G: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
41. Strasser EF, Berger TG, Weisbach V, Zimmermann R, Ringwald J, Schuler-Thurner B, Zingsem J, Eckstein R: Comparison of two apheresis systems for the collection of CD14+ cells intended to be used in dendritic cell culture. Transfusion 2003;43: 1309-1316.
42. Wolf C, Meyer M, Riggert J: Leukapheresis for the extraction of monocytes and various lymphocyte subpopulations from peripheral blood: product quality and prediction of the yield using different harvest procedures. Vox Sang 2005;249-255.
43. Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Biserka P, Dada A, Niemand C, Assenmacher M, Orso E, et al.: Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 2006;12:267-274.
44. Allan SE, Alstad AN, Merindol N, Crellin NK, Amendola M, Bacchetta R, Naldini L, Roncarolo MG, Soudeyns H, Levings MK: Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 2008;16:194-202.
45. Bruno L, Merkenschlager M: Directing T cell differentiation and function with small molecule inhibitors. Cell Cycle 2009;7:2296-2298.
46. Macaulay IC, Tijssen MR, Thijssen-Timmer DC, Gusnanto A, Steward M, Burns P, Langford CF, Ellis P, Dudbridge F, Zwaginga JJ, et al.: Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood 2006;109:3260-3269.
47. O'Connor N, Salles I, Cvejic A, Watkins NA, Walker A, Garner S, Macaulay IC, Steward M, Zwaginga J, Bray S, et al.: Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood 2008;113:4754-5762.
48. Koenen HJPM, Fasse E, Joosten I: CD27/CFSEbased ex vivo selection of highly suppressive alloantigen- specific human regulatory T cells. J Immunol 2005;174:7573-7583.
49. Birebent B, Lorho R, Lechartier H, de Guibert S, Alizadeh M, Vu N, Beauplet A, Robillard N, Semana G: Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression. Eur J Immunol 2004;34:3485-3496.
50. Baecher-Allan C, Wolf E, Hafler DA: MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006;176:4622-4631.
51. Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, de St.Groth BF, et al.: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-1711.
52. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell'acqua ML, et al.: Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-1232.
53. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM: GARP (LRRC32) is essential for the surface expression of latent TGF-(beta) on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 2009; doi: 10.1073/ pnas.0901944106.